DAVIS, Calif., Sept. 23, 2019 /PRNewswire/ -- Arcadia
Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based
approaches to enhancing the quality and nutritional value of crops
and food ingredients, today announced the U.S. Patent and Trademark
Office has awarded the company a patent for reduced gluten grains.
This unique attribute was developed through Arcadia's in-house breeding platform, which
brings novel food innovations to consumers. The patent is the 17th
in Arcadia's GoodWheat™ portfolio
of non-genetically modified (non-GM) wheat varieties, which
includes high-fiber resistant starch, extended shelf life and now
reduced gluten.
"This patent reaffirms Arcadia's position as a leader in crop
innovation, particularly in optimizing crops for higher nutritional
value," said Randy Shultz, Ph.D.,
vice president of research and development at Arcadia Biosciences.
"We continue to bring valuable and healthy innovation to wheat –
one of the most widely consumed crops in the world – through our
GoodWheat portfolio."
Arcadia's reduced gluten wheat
contains 75 percent less allergenic gluten content than traditional
wheat, while also delivering improved protein quality and increased
levels of essential amino acids such as lysine and histidine. Foods
made with Arcadia's reduced gluten
wheat flour offer the same baking quality, taste and texture as
traditional wheat. The company plans to offer a retail version to
consumers later this year, in what will be the company's first-ever
direct-to-consumer product offering.
"This is really an exciting time for Arcadia's GoodWheat portfolio," added
Sarah Reiter, chief commercial
officer at Arcadia. "Our dedicated
investments and proprietary scientific research into wheat are
finally coming to fruition through commercialization of our high
fiber, extended shelf life and reduced gluten wheat flour
ingredients. Our newest offering caters to a growing number of
consumers looking to reduce their gluten intake, either as a result
of a wheat sensitivity or simply because they feel or perform
better when following a diet with lower levels of gluten."
According to market research conducted by The Connell Group on
behalf of Arcadia in 2018, 26
percent of consumers reported they were actively seeking to reduce
their gluten intake or avoid it altogether. Additionally, according
to the "Global Gluten Free Products Market" report, the global
gluten-free products market is projected to reach
$9.14 billion in value by 2023.
About Arcadia Biosciences, Inc.
Arcadia Biosciences
(Nasdaq: RKDA) develops and markets high-value food ingredients and
nutritional oils that help meet consumer demand for a healthier
diet. Arcadia's GoodWheat™ branded
ingredients deliver health benefits to consumers and enable
consumer packaged goods companies to differentiate their brands in
the marketplace. The company's agricultural traits are being
developed to enable farmers around the world to be more productive
and minimize the impact of agriculture on the environment. Arcadia
Specialty Genomics is a business unit within Arcadia Biosciences
dedicated to the optimization and standardization of cannabis plant
content, quality, resiliency and yield. For more information,
visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements regarding our planned commercial launch of reduced
gluten products in the fourth quarter of 2019 and our estimate of
the size of the gluten-free food market in 2020. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to:
Arcadia's and its partners' and
affiliates' ability to develop and sell commercial products
incorporating their traits, and complete the regulatory review
process for such products; Arcadia's compliance with laws and regulations
that impact Arcadia's business,
and changes to such laws and regulations; Arcadia's ability to capture revenue in 2019
and beyond; the growth of the global flour market; Arcadia's future capital requirements and
ability to satisfy its capital needs; and the other risks set forth
in Arcadia's filings with the
Securities and Exchange Commission from time to time, including the
risks set forth in Arcadia's
Annual Report on Form 10-K for the year ended December 31, 2018 and other filings. These
forward-looking statements speak only as of the date hereof, and
Arcadia Biosciences, Inc. disclaims any obligation to update these
forward-looking statements.
Twitter: @ArcadiaAg on Twitter
LinkedIn: Arcadia Biosciences
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-granted-us-patent-for-reduced-gluten-goodwheat-300922933.html
SOURCE Arcadia Biosciences